Literature DB >> 1783992

Model representation of salicylate pharmacokinetics using unbound plasma salicylate concentrations and metabolite urinary excretion rates following a single oral dose.

J Shen1, S Wanwimolruk, R D Purves, E G McQueen, M S Roberts.   

Abstract

The pharmacokinetics of salicylic acid (SA) and its metabolites have been studied in 5 volunteers after administration of 3 g salicylic acid (as sodium salicylate) and collection of serial samples of blood and urine. SA and its metabolites were assayed with a HPLC method specific for each species. The urinary excretion rates of individual metabolites were analyzed using unbound plasma SA concentrations and Lineweaver-Burke plots. The analysis confirmed that the formation of SA urate (SU) and SA phenolic glucuronide (SPG) metabolites are saturable processes, and showed that the Michaelis-Menten values derived are consistent with earlier estimates derived solely from urinary data. The unbound salicylate plasma concentration-time profiles were then analyzed with various models assuming either saturable clearances for metabolite formation and/or saturable protein binding. The data were best described with a model that included both saturable protein binding and saturable metabolism. The model assumed first-order absorption kinetics and instantaneous distribution into extravascular and tissue compartments. The model was validated by comparing predicted relationships between the apparent volume of distribution, clearance, and plasma salicylate concentrations with previous relationships obtained using steady state data.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1783992     DOI: 10.1007/bf01062964

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  27 in total

1.  Protein binding of salicylate in uremic and normal plasma.

Authors:  O Borgå; I O Cederlöf; V A Ringberger; A Norlin
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

2.  Relationship between dose and plateau levels of drugs eliminated by parallel first-order and capacity-limited kinetics.

Authors:  T Tsuchiya; G Levy
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

3.  Salicylate accumulation kinetics in man.

Authors:  G Levy; T Tsuchiya
Journal:  N Engl J Med       Date:  1972-08-31       Impact factor: 91.245

4.  The kinetics of elimination of salicylic acid and the formation of gentisic acid.

Authors:  D R Boreham; B K Martin
Journal:  Br J Pharmacol       Date:  1969-09       Impact factor: 8.739

5.  Two-compartment model for a drug and its metabolite: application to acetylsalicylic acid pharmacokinetics.

Authors:  M Rowland; L Z Benet; S Riegelman
Journal:  J Pharm Sci       Date:  1970-03       Impact factor: 3.534

6.  Pharmacokinetics of salicylate elimination in man.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1965-07       Impact factor: 3.534

7.  Salicylate metabolite kinetics after several salicylates.

Authors:  F Bochner; G G Graham; B E Cham; D M Imhoff; T M Haavisto
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

8.  Theoretical analysis of the binding of salicylate by human serum albumin: the relationship between free and bound drug and therapeutic levels.

Authors:  W D Wosilait
Journal:  Eur J Clin Pharmacol       Date:  1976-02-06       Impact factor: 2.953

9.  Clinical pharmacokinetics of salicylates: a re-assessment.

Authors:  G Levy
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

10.  Salicylate clearance, the resultant of protein binding and metabolism.

Authors:  D E Furst; T N Tozer; K L Melmon
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

View more
  7 in total

1.  Metabolite mean transit times in the liver as predicted by various models of hepatic elimination.

Authors:  G D Mellick; Y G Anissimov; A J Bracken; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

2.  Dermal and underlying tissue pharmacokinetics of salicylic acid after topical application.

Authors:  P Singh; M S Roberts
Journal:  J Pharmacokinet Biopharm       Date:  1993-08

Review 3.  Pharmacokinetic considerations in clinical toxicology: clinical applications.

Authors:  Darren M Roberts; Nick A Buckley
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

4.  Acetylsalicylic acid--inducer of cytochrome P-450 2E1?

Authors:  D Pankow; B Damme; K Schrör
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

5.  Mechanisms of action of paracetamol and related analgesics.

Authors:  Garry G Graham; Kieran F Scott
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

Review 6.  Drug structure-transport relationships.

Authors:  Michael S Roberts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-24       Impact factor: 2.745

7.  Unlabeled aspirin as an activatable theranostic MRI agent for breast cancer.

Authors:  KowsalyaDevi Pavuluri; Ethan Yang; Vinay Ayyappan; Kanchan Sonkar; Zheqiong Tan; Caitlin M Tressler; Shaowei Bo; Adnan Bibic; Kristine Glunde; Michael T McMahon
Journal:  Theranostics       Date:  2022-01-24       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.